KU-55933
Code | Size | Price |
---|
TAR-T2685-5mg | 5mg | £105.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2685-1mL | 1 mL * 10 mM (in DMSO) | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2685-10mg | 10mg | £119.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2685-25mg | 25mg | £153.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2685-50mg | 50mg | £204.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2685-100mg | 100mg | £302.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor.
CAS:
587871-26-9
Formula:
C21H17NO3S2
Molecular Weight:
395.49
Pathway:
PI3K/Akt/mTOR signaling; DNA Damage/DNA Repair; Autophagy
Purity:
0.998
SMILES:
O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1
Target:
ATM/ATR; DNA-PK; PI3K; mTOR; Autophagy
References
1. Hickson I, et al. Cancer Res. 2004, 64(24), 9152-9159.
2. Soleimani R, et al. Aging. 2011, 3(8), 782-793.
3. Ivanov VN, et al. Cancer Res. 2009, 69(8), 3510-3519.
4. Hu L, Li B, Chen G, et al. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe. Journal of Experimental & Clinical Cancer Research. 2020, 39(1): 1-14.
5. Huang C Y, Hsieh F S, Wang C Y, et al. Supplementary Methods Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ATM-mediated DNA damage response. EUROPEAN JOURNAL OF CANCER.